Proteomics

Dataset Information

0

Discovery of an ApoE4-Targeted Small-Molecule SirT1 Enhancer for the Treatment of Alzheimer’s Disease

ABSTRACT: Herein we describe the discovery of an orally brain-22 permeable small-molecule, DDL-218, that enhanced SirT1 in ApoE4-expressing neuronal cells 23 and a murine AD model. DDL-218 increased the transcription factor NFYb resulting in 24 upregulation of PRMT5. Mechanistic and modeling studies show that binding of ApoE4 to the 25 SirT1 gene promoter can be displaced by PRMT5 leading to increased SirT1 transcription. DDL-26 218 treatment elicited improvement in memory in the AD model, suggesting that DDL-218 27 enhancement of neurotrophic SirT1 in the brain has potential to modulate neuronal activity that 28 may clinically provide an improvement in cognitive function and complement the current anti-29 Aβ antibody monotherapy. Our findings support further development of DDL-218 as a novel 30 ApoE4-targeted therapeutic candidate for AD.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Jesus Campagna  

LAB HEAD: Varghese John

PROVIDER: PXD060379 | Pride | 2025-05-07

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
wc_QE_082124_John_Ainsley-A0.raw Raw
wc_QE_082124_John_Ainsley-A1.raw Raw
wc_QE_082124_John_Ainsley-A2.raw Raw
wc_QE_082124_John_Ainsley-A3.raw Raw
wc_QE_082124_John_Ainsley-A4.raw Raw
Items per page:
1 - 5 of 10
altmetric image

Publications

Decreased expression of sirtuin 1 (SirT1) has been implicated in Alzheimer's disease (AD), and as we previously reported, is related to transcriptional repression by the major risk factor for sporadic AD, apolipoprotein E4 (ApoE4). Herein we describe the discovery of an orally brain-permeable small-molecule, DDL-218, that enhanced SirT1 in ApoE4-expressing neuronal cells and a murine AD model. DDL-218 increased the transcription factor NFYb resulting in upregulation of PRMT5. Mechanistic and mod  ...[more]

Similar Datasets

Transcriptomics Comparaison of APOE4 and APOE3 transcriptomic profiles from derived cell lines in absence or presence of an inflammatory stimulus
2021-02-01 | E-MTAB-9625 | biostudies-arrayexpress
Transcriptomics Neuronal APOE4 removal strongly protects against Tau-mediated gliosis, neurodegeneration, and myelin deficits
2023-01-06 | GSE221215 | GEO
Proteomics Alzheimer’s disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model
2024-08-22 | PXD053544 | Pride
Transcriptomics A SAGE approach to discovery of apolipoprotein E4 allele-specific genes involved in increased risk in Alzheimer disease
2007-01-13 | GSE6677 | GEO
Proteomics Isoform-dependent lysosomal degradation and internalization of Apolipoprotein E requires autophagy proteins
2022-01-18 | PXD031016 | Pride
Proteomics Domino-like Effect of C112R Mutation on APOE4 Aggregation and Its Suppression by Alzheimer’s Disease Drug Candidate
2023-07-20 | PXD036416 | Pride
Transcriptomics APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release
2023-09-01 | GSE242153 | GEO
Proteomics Comparative profiling of the synaptic proteome from Alzheimer’s disease patients with focus on the APOE genotype
2020-05-26 | PXD013753 | Pride
Transcriptomics The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation
2023-09-21 | GSE217854 | GEO
Transcriptomics Microglia Depletion Reduces Human Neuronal APOE4-Driven Pathologies in a Chimeric Alzheimer’s Disease Model
2024-10-25 | GSE248020 | GEO